N端截短GAD自身抗体改善成人起病糖尿病临床表型分型:Action LADA 12
研究纳入Action LADA研究中1114例成人起病糖尿病患者(初判1型511例、2型603例),用放射结合法复测全长GAD65自身抗体(f-GADA)和N端截短GAD65自身抗体(t-GADA)。t-GADA阳性者胰岛素治疗风险(OR 4.69,95%CI 3.57–6.17)高于f-GADA阳性者(OR 3.86,95%CI 2.95–5.06);仅f-GADA阳性而t-GADA阴性者表型类似2型糖尿病。结论认为N端截短GAD65自身抗体与自身免疫性1型糖尿病临床表型相关并预测胰岛素治疗。
要点
- t-GADA阳性者胰岛素治疗风险OR 4.69(95%CI 3.57–6.17),高于f-GADA阳性者的OR 3.86(95%CI 2.95–5.06)。
- 仅f-GADA阳性而t-GADA阴性者表型类似2型糖尿病,进展至胰岛素治疗风险低。
- 与N端GAD65限制性GADA者相比,t-GADA阳性者诊断年龄更轻(p=0.005)、更瘦(p<0.0001)、多自身抗体比例更高(28.3% vs 7.3%,p=0.0005)。
核心结论
- 在成人起病糖尿病患者中,N端截短GAD65自身抗体的存在与自身免疫性1型糖尿病的临床表型相关,并预测胰岛素治疗。
研究设计与样本
- 从Action LADA研究中纳入1114例成人起病糖尿病患者,其中初判1型糖尿病511例、2型糖尿病603例,复测样本f-GADA和t-GADA。
主要发现
- 478例f-GADA阳性,431例t-GADA阳性,628例两种抗体均阴性。
- t-GADA阳性者胰岛素治疗风险OR 4.69(95%CI 3.57, 6.17),f-GADA阳性者OR 3.86(95%CI 2.95, 5.06),与糖尿病病程无关。
- 55例f-GADA阳性但t-GADA阴性者表型类似2型糖尿病,进展至胰岛素治疗风险低。
- 与N端GAD65限制性GADA者相比,t-GADA阳性者诊断年龄更轻(p=0.005)、更瘦(p<0.0001)、多糖尿病相关自身抗体比例更高(28.3% vs 7.3%,p=0.0005)。
关键数值与推荐
- t-GADA阳性者胰岛素治疗风险OR 4.69(95%CI 3.57, 6.17)。
- f-GADA阳性者胰岛素治疗风险OR 3.86(95%CI 2.95, 5.06)。
- t-GADA阳性者多糖尿病相关自身抗体比例28.3%,N端GAD65限制性GADA者为7.3%(p=0.0005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Adult-onset type 1 diabetes, in which the 65 kDa isoform of GAD (GAD65) is a major autoantigen, has a broad clinical phenotype encompassing variable need for insulin therapy. This study aimed to evaluate whether autoantibodies against N-terminally truncated GAD65 more closely defined a type 1 diabetes phenotype associated with insulin therapy. METHODS: Of 1114 participants with adult-onset diabetes from the Action LADA (latent autoimmune diabetes in adults) study with sufficient sera, we selected those designated type 1 (n = 511) or type 2 diabetes (n = 603) and retested the samples in radiobinding assays for human full-length GAD65 autoantibodies (f-GADA) and N-terminally truncated (amino acids 96-585) GAD65 autoantibodies (t-GADA). Individuals' clinical phenotypes were analysed according to antibody binding patterns. RESULTS: Overall, 478 individuals were f-GADA-positive, 431 were t-GADA-positive and 628 were negative in both assays. Risk of insulin treatment was augmented in t-GADA-positive individuals (OR 4.69 [95% CI 3.57, 6.17]) compared with f-GADA-positive individuals (OR 3.86 [95% CI 2.95, 5.06]), irrespective of diabetes duration. Of 55 individuals who were f-GADA-positive but t-GADA-negative, i.e. with antibody binding restricted to the N-terminus of GAD65, the phenotype was similar to type 2 diabetes with low risk of progression to insulin treatment. Compared with these individuals with N-terminal GAD65-restricted GADA, t-GADA-positive individuals were younger at diagnosis (p = 0.005), leaner (p < 0.0001) and more often had multiple diabetes-associated autoantibodies (28.3% vs 7.3%; p = 0.0005). CONCLUSIONS/INTERPRETATION: In individuals with adult-onset diabetes, presence of N-terminally truncated GAD65 autoantibodies is associated with the clinical phenotype of autoimmune type 1 diabetes and predicts insulin therapy.
引用
- Achenbach P, Hawa MI, Krause S, et al. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia. 2018. PMID: 29619531. doi:10.1007/s00125-018-4605-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。